Contact us
May 23, 2025

HanchorBio to Present Interim Clinical Data at ASCO 2025 Annual Meeting

【TAIPEI, SHANGHAI, and SAN FRANCISCO, May 23, 2025】– HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announced that interim clinical data from its lead immunotherapy product, HCB101, has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago, Illinois.
The accepted abstract (#2584: Phase 1 trial of HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, in subjects with advanced cancers) highlights emerging data from the ongoing Phase 1 dose-escalation trial (NCT05892718) of HCB101, a differentiated SIRPα-Fc fusion protein rationally engineered to enhance phagocytosis and innate immune activation, without the hematologic toxicity that has hindered earlier CD47-targeting therapies. HCB101 is being evaluated as monotherapy in patients with advanced solid tumors or relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs). The poster presentation is scheduled for June 2, 2025, during the ASCO Immunotherapy session.
“HCB101 was designed to unlock the full potential of macrophage checkpoint inhibition by overcoming key limitations of legacy CD47 programs,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “The ASCO presentation represents an important step in our strategy to build durable, best-in-class immunotherapies driven by innate immunity. We look forward to engaging with the oncology community, including scientific leaders, collaborators, and potential partners, as we advance HCB101 into the next phase of clinical development.”
HCB101 was developed using HanchorBio’s proprietary FBDB™ platform, which combines Fc engineering and SIRPα optimization to achieve high-affinity binding and immune effector activation. Preclinical studies demonstrated robust anti-tumor activity and favorable tolerability, supporting its clinical advancement.
HanchorBio is actively exploring strategic collaborations to accelerate global development and unlock the full potential across oncology and autoimmune indications.
Apr 15, 2025
HanchorBio Announces Second Taiwan TFDA Approval for HCB101 Combination Therapy in Advanced Head and Neck Cancer
HanchorBio Inc., a global biotechnology company developing innovative immuno-biomedicines to address significant unmet medical needs in oncology, today announced that the Taiwan Food and Drug Administration (TFDA) has approved a second investigator-initiated trial (IIT) evaluating the safety and efficacy of HCB101 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who are refractory to platinum-based chemotherapy. The study will take place at Taipei Veterans General Hospital and Linkou Chang Gung Memorial Hospital. This marks the second TFDA-approval IIT of HCB101 in combination with standard-of-care (SOC) therapies, following the recently announced IIT approval for a metastatic colorectal cancer (mCRC) study. The new approval underscores HanchorBio’s strategic focus on expanding HCB101’s clinical development MOA (mode of action) based immunotherapy combinations across multiple solid tumors with unmet medical needs.
Jun 03, 2025
HanchorBio Presents Promising Phase 1 HCB101 Data at ASCO 2025 – Confirmed Partial Response Observed in Solid Tumor and Lymphoma Patients
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today presented interim data from its lead immunotherapy product, HCB101, following its poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 – June 4 in Chicago, Illinois. The data, featured in a poster session, demonstrated favorable safety, high CD47 receptor occupancy, and early clinical signs of anti-tumor activity, including confirmed partial response (PR) in patients with head and neck cancer (HNSCC) and marginal zone lymphoma.